Evidence map›Paper›PMID 37978365›Full record

Trial reportBMC musculoskeletal disorders2023

Blood-conserving and therapeutic efficacy of intravenous tranexamic acid at different time points after primary total knee arthroplasty with tourniquet application: a randomised controlled trial.

Mingyou Wang, Yuping Lan, Hongping Wang, Chunyu Chen, Zhu Mei, Qifeng Tao

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC musculoskeletal disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mingyou WangDepartment of Orthopaedics, Panzhihua Central Hospital, 34# Yikang road, Panzhihua, Sichuan, 617000, People's Republic of China.
Yuping LanDepartment of Orthopaedics, Panzhihua Central Hospital, 34# Yikang road, Panzhihua, Sichuan, 617000, People's Republic of China.
Hongping WangDepartment of Orthopaedics, Panzhihua Central Hospital, 34# Yikang road, Panzhihua, Sichuan, 617000, People's Republic of China.
Chunyu ChenDepartment of Orthopaedics, Panzhihua Central Hospital, 34# Yikang road, Panzhihua, Sichuan, 617000, People's Republic of China.
Zhu MeiDepartment of Orthopaedics, Panzhihua Central Hospital, 34# Yikang road, Panzhihua, Sichuan, 617000, People's Republic of China.
Qifeng TaoDepartment of Orthopaedics, Panzhihua Central Hospital, 34# Yikang road, Panzhihua, Sichuan, 617000, People's Republic of China. wmy1241317@163.com.
Panzhihua Central Hospital · CN

Funding

The Primary Health Development Research Center of Sichuan Province Program SWFZ21-C-111
6 · The paper itself

Abstract

backgroundThe use of a tourniquet in combination with tranexamic acid (TXA) not only ensures clear vision, reduces intraoperative blood loss and shortens operative time but also improves cement-bone inter-digitation in total knee arthroplasty (TKA). However, there is no proof whether the blood flow blocking effect of tourniquet affects the antifibrinolytic effect of TXA, and the optimal timing of TXA administration is still unclear. Therefore, this study aims to investigate the effect of the first dose of TXA administered intravenously before tourniquet compression and release in TKA on perioperative blood loss and therapeutic efficacy in patients.

methodsIn this double-blind trial, 90 patients undergoing primary TKA were randomised into 2 groups: Group A, patients received intravenous TXA 10 min before tourniquet compression (20 mg/kg) and 3, 6 and 24 h later (10 mg/kg), and Group B, patients were treated the same as those in Group A but received intravenous TXA before tourniquet release. The primary outcomes were changes in blood loss, haemoglobin and haematocrit. Secondary outcomes included operation and tourniquet times, blood transfusion rate, subcutaneous petechiae and circumferential changes in the operated limb, visual analogue scale (VAS) score, hospital for special surgery (HSS) score, length of stay (LOS) postoperatively, complications and patient satisfaction.

resultsNo statistically significant difference was found between the 2 groups with regard to age, sex, weight, body mass index (BMI), Kellgren-Lawrence class, preoperative blood volume, preoperative laboratory values, operation and tourniquet times, transfusion rate, knee circumference, preoperative HSS, or VAS score (P:n.s.). There was no significant difference in intraoperative blood loss (IBL) (52.7 ml vs. 63.4 ml, P = 0.07), hidden blood loss (HBL) (91.4 ml vs. 119.9, P = 0.4) or total blood loss (TBL) (144.1 ml vs. 183.3 ml, P = 0.72) between Groups A and B. Haemoglobin, haematocrit and red blood cell count (RBC) dropped to a low point on postoperative day 3 and then rebounded, returning to normal levels on day 21, and the trend of change between the 2 groups was not statistically significant (P:n.s.). There was no significant difference in subcutaneous ecchymosis incidence, knee swelling rate, HSS score, VAS score, LOS postoperatively, complication rate or patient satisfaction (P:n.s.).

conclusionTXA was administered intravenously prior to tourniquet compression could effectively reduce blood loss in patients who had undergone total knee arthroplasty. However, there was no significant difference in knee swelling rate, subcutaneous bruising and petechiae incidence, knee function, complication rate or satisfaction between patients who TXA was given intravenously before tourniquet compression and release in primary TKA.

Indexed as

Antifibrinolytic AgentsArthroplasty, Replacement, KneePurpuraTranexamic AcidAdministration, IntravenousBlood Loss, SurgicalHemoglobinsHumansTourniquetsAntifibrinolytic AgentsHemoglobinsTranexamic AcidApplication and studyBlood lossEcchymosis and swellingTotal knee arthroplastyTourniquetTranexamic acid

Identifiers

PMID37978365
PMCPMC10655351
OpenAlexW4388765837

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.